Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 8,376 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Capsule Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Enhancing Adaptations to Exercise

NCT03350906
View directory record Official record
Conditions
Inflammation
Interventions
n3-PUFA, Placebo, Biopsy, Body Composition Scan
Drug · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 85 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 2 Interventional Results available

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

NCT01320033
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD2475/101 40 mg, Doxycycline 100 mg, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
662 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Hot Springs, Arkansas • Los Angeles, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
ARN-75039 oral capsules, Placebo
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Not applicable Interventional

Study of Artelon FLEXBAND® for Patients Undergoing Soft Tissue Reconstruction of the Anterior Talofibular Ligament (ATFL) to Treat Lateral Ankle Instability

NCT06638138
View directory record Official record
Conditions
Lateral Ankle Instability
Interventions
Flexband
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 24, 2026, 2:55 PM EDT
Not listed Phase 2 Interventional

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

NCT04939116
View directory record Official record
Conditions
Glomerular Disease, Proteinuria
Interventions
ANG-3070, Placebo
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
18
States / cities
Birmingham, Alabama • Northridge, California • Vacaville, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

NCT02088684
View directory record Official record
Conditions
Breast Cancer
Interventions
LEE011, BYL719, fulvestrant, BKM120
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 2 Interventional

7-Keto DHEA for the Treatment of PTSD

NCT01861847
View directory record Official record
Conditions
PTSD
Interventions
7-Keto Dehydroepiandrosterone, Placebo
Drug
Lead sponsor
Humanetics Corporation
Industry
Eligibility
18 Years to 64 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bay Pines, Florida
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action

NCT02900352
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Zonisamide, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 70 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Farmington, Connecticut • New Haven, Connecticut • West Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

NCT04054206
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MN-166
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Citicoline Treatment of Methamphetamine Dependence

NCT00950352
View directory record Official record
Conditions
Methamphetamine Dependence
Interventions
Citicoline, Placebo
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 45 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 24, 2026, 2:55 PM EDT
Active, not recruiting Not applicable Interventional

Effects of Vitamin K on Lower-extremity Function in Adults With Osteoarthritis:

NCT05505552
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Vitamin K, Placebo
Dietary Supplement
Lead sponsor
Tufts University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals

NCT01431690
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
warfarin, omefas, omega-3-acid ethyl esters
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2015 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments

NCT01490697
View directory record Official record
Conditions
Post-traumatic Stress Disorder
Interventions
Mifepristone, d-Cycloserine, Placebo-matching Mifepristone, Placebo-matching d-Cycloserine (DCS)
Drug
Lead sponsor
Roger K. Pitman, MD
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2017 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

NCT05558410
View directory record Official record
Conditions
Acute Pain
Interventions
Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 24, 2026, 2:55 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia

NCT07284290
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease Dementia, Healthy Controls
Interventions
Syn-One skin biopsy, Multi modal MRI, Assessment of dynamic EEG features over 48-hour periods across all study aims, Plasma biomarkers, Galantamine HBr extended-release 8mg capsules (8mg ER).
Procedure · Diagnostic Test · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
50 Years to 89 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Not applicable Interventional Results available

Pregabalin for the Treatment of Pain After Posterior Spinal Fusions

NCT01366196
View directory record Official record
Conditions
Lumbar Spinal Fusions
Interventions
Pregabalin 150 mg, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
21 Years to 80 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 24, 2026, 2:55 PM EDT
Terminated Phase 2 Interventional

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

NCT01579279
View directory record Official record
Conditions
Diabetic Neuropathic Pain
Interventions
ABT-652 6 mg, ABT-652 12 mg, ABT-652 12 mg - 18 mg, Placebo, Duloxetine
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Anaheim, California • Walnut Creek, California • Milford, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

NCT03739203
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
58
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-104, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate a Probiotic in Healthy Subjects With a History of Abdominal Discomfort and Bloating

NCT01099696
View directory record Official record
Conditions
Abdominal Discomfort, Bloating
Interventions
B. infantis 35624, placebo
Dietary Supplement
Lead sponsor
Procter and Gamble
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
10
States / cities
Chicago, Illinois • Rockford, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

NCT01939496
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
54
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

NCT05140096
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Acalabrutinib, Fluconazole, Isavuconazole
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2021 · Synced Oct 24, 2026, 2:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01303796
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Sapacitabine, Decitabine
Drug
Lead sponsor
Cyclacel Pharmaceuticals, Inc.
Industry
Eligibility
70 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 24, 2026, 2:55 PM EDT